Committed to providing exceptional care and continued support to patients, families and caregivers.

Menu

NCT02089685

Disease Type: Melanoma
Status: Open

Trial Information

A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Click here for more information

This trial is available at:

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

For more information, please contact: